@article{TAU705,
author = {Zsuzsanna Mihály and Alexisz Panajotu and Balázs Győrffy},
title = {Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?},
journal = {Translational Andrology and Urology},
volume = {1},
number = {3},
year = {2012},
keywords = {},
abstract = {In the course of the last decade the therapy of renal cell carcinoma (RCC) stepped into a new era as targeted therapies changed protocols and the prognosis of patients as well. Could this successful start with sunitinib and sorafenib be continued by more potent agents? Because objective response rates (ORR) are still far from ideal (none of them reach 50%), other targeted molecular approaches need to be developed. Consequently, a number of currently ongoing trials focus on confirming potential new agents for the systemic therapy of metastatic RCC (mRCC). One of these, tivozanib is a tyrosine kinase inhibitor blocking all three VEGF receptors (pan-VEGF inhibitor), thus it potentially possesses all the indications of the currently recommended Sorafenib, Pazopanib and Axitinib.},
issn = {2223-4691}, url = {https://tau.amegroups.org/article/view/705}
}